MNEXSPIKE
The FDA has approved MNEXSPIKE, a vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2. The approval applies to individuals aged 65 and older, as well as those aged 12 through 64 years.
This update affects the manufacturer of MNEXSPIKE, healthcare providers administering the vaccine, and regulatory/compliance professionals overseeing vaccine distribution and safety reporting for pediatric and geriatric populations.
The source indicates a specific bifurcated age indication for this vaccine product. This suggests that regulatory and clinical operations teams must ensure that labeling, promotional materials, and administration protocols accurately distinguish between the 12-64 and 65+ cohorts. The incomplete nature of the source text Regarding the 12-64 age group suggests there may be additional specific conditions or nuances for that population that require verification via the full prescribing information.
Regulatory teams should update product labeling and internal databases to reflect the specific age-based indications. Pharmacovigilance departments must configure safety monitoring protocols for the newly approved recipient populations. Quality assurance should ensure that distribution and clinical trial protocols align with these age-specific parameters.
MNEXSPIKE is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MNEXSPIKE is approved for use in individuals who are:<br> 65 years of age and older, or<br> 12 years through 64 years of age with
Open in openFDA / FDA.gov